環亞國際醫療集團(01143.HK)擬3780萬港元受讓元析代理協議
格隆匯1月19日丨環亞國際醫療集團(01143.HK)發佈公吿,2022年1月18日,施明耀作為轉讓人、公司及公司間接全資附屬環亞國際輔助生殖科技集團有限公司作為受讓人訂立轉讓契據,據此,轉讓人同意向受讓人轉讓其在代理協議中及就此享有的所有權利、義務、擁有權、權益及利益,代價為3780萬港元,將以公司於完成後向轉讓人(或其代名人)配發及發行2.3億股代價股份的方式償付。代價股份發行價為每股約0.164港元,相當於1月18日收市價0.177港元折讓約7.3%。
根據披露,轉讓人與元析訂立代理協議,據此,元析委任轉讓人為其獨家代理,並向轉讓人授出獨家權利,於中國香港及中國澳門分銷一系列測試及測量產品及委任轉讓人為其非獨家代理並向轉讓人授出非獨家權利,於中國內地以外亞洲地區(中國香港及中國澳門除外)分銷產品及售後服務。產品包括紫外分光光度計、可見光分光光度計、總有機碳分析儀及微波分解系統,廣泛用於環境、食品、化粧品、醫藥、生命科學及化學領域。
董事會認為轉讓為集團提供透過納入於中國擁有逾十年經驗且具規模的科學儀器生產商元析所生產測試及測量設備產品藉以擴展電子製造服務及分銷產品業務產品組合的良機。此為集團把握由對實驗室設備不斷增長的需求所驅動的亞洲市場的增長潛力(尤其是於製藥、生命科學及化學領域)提供商業上可行的機會並有利於集團的中長期發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.